Coverage
Filings
| Filing | Date |
|---|---|
| GSK announces positive Blenrep DREAMM-8 results | 7 Mar 2024 |
| ViiV LAI vs oral SOC data in adherence-challenged | 6 Mar 2024 |
| New ViiV LA formulation potential 4-month dosing | 5 Mar 2024 |
| GSK Annual Report 2023 on Form 20-F | 5 Mar 2024 |
| GSK publishes Annual Report 2023 | 1 Mar 2024 |
| Total Voting Rights | 1 Mar 2024 |
| Statement: Zantac (ranitidine) litigation | 29 Feb 2024 |
| Directorate Change |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 29 Feb 2024 |
| GSK announces positive EAGLE-1 headline results | 26 Feb 2024 |
| Director/PDMR Shareholding | 26 Feb 2024 |
| Director/PDMR Shareholding | 22 Feb 2024 |
| ViiV LAI superior to orals in adherence-challenged | 21 Feb 2024 |